Does Neoleukin Therapeutics Inc (NLTX) Have What it Takes to be in Your Portfolio Thursday?

Thursday, March 09, 2023 12:20 PM | InvestorsObserver Analysts

Mentioned in this article

Does Neoleukin Therapeutics Inc (NLTX) Have What it Takes to be in Your Portfolio Thursday?

The 46 rating InvestorsObserver gives to Neoleukin Therapeutics Inc (NLTX) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 74 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, NLTX’s 46 overall rating means the stock scores better than 46 percent of all stocks.

NLTX has an Overall Score of 46. Find out what this means to you and get the rest of the rankings on NLTX!

See Full NLTX Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 46 would rank higher than 46 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Neoleukin Therapeutics Inc Stock Today?

Neoleukin Therapeutics Inc (NLTX) stock has risen 31.52% while the S&P 500 is lower by -0.04% as of 12:19 PM on Thursday, Mar 9. NLTX has gained $0.17 from the previous closing price of $0.53 on volume of 9,325,610 shares. Over the past year the S&P 500 is down -6.72% while NLTX is lower by -72.66%. NLTX lost -$1.07 per share the over the last 12 months. Click Here to get the full Stock Report for Neoleukin Therapeutics Inc stock.